Literature DB >> 28457725

Non-surgical treatments for hidradenitis suppurativa: A systematic review.

E Robert1, F Bodin1, C Paul2, M-P Konstantinou2, Y Gall2, J-L Grolleau3, J Laloze3, B Chaput4.   

Abstract

INTRODUCTION: The management of hidradenitis suppurativa is multidisciplinary, involving general measures, medical treatment and surgery. Non-surgical treatments, often first-line procedures, mainly concern forms of low-to-moderate severity or, conversely, very severe forms in non-operable patients or those refusing surgery. While many treatments have been attempted, few randomized controlled trials have been conducted, so the choice of treatments is most often based on the personal experience of the clinicians. The objective of this systematic review is to propose a synthetic analysis of the currently available non-surgical procedures.
METHODS: This systematic review of the literature was conducted in accordance with the PRISMA criteria. We searched for articles in the Medline®, PubMed Central, Embase and Cochrane databases published between January 2005 and September 2015.
RESULTS: Sixty-four articles were included. They generally had a low level of evidence; indeed, the majority of them were retrospective observational studies. They involved biotherapy (44%), dynamic phototherapy (16%), antibiotics (11%), Laser (8%), retinoids (6%) and immunosuppressive therapies, anti-inflammatory drugs, zinc, metformin, gammaglobulins and fumarates.
CONCLUSIONS: None of the non-surgical treatments can treat all stages of the disease and offer long-term remission. Antibiotics and biotherapy seem to have real effectiveness but their effect remains suspensive and the disease is almost certain to reappear once they are stopped. As regards antibiotics, no association has shown their superiority in a study with a high level of evidence. And while some biotherapies seem quite effective, due to their side effects they should be reserved for moderate-to-severe, resistant or inoperable forms of the disease. Randomized controlled studies are needed before valid conclusions can be drawn. In the resistant or disabling forms, it is consequently advisable to orientate to the greatest possible extent towards radical surgery, which is the only treatment allowing hope for cure.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Antibiotics; Antibiotique; Biologic therapies; Biothérapie; Hidrosadénite suppurée; Maladie de Verneuil; Revue systématique; Systematic review; Verneuil's disease

Mesh:

Substances:

Year:  2017        PMID: 28457725     DOI: 10.1016/j.anplas.2017.03.012

Source DB:  PubMed          Journal:  Ann Chir Plast Esthet        ISSN: 0294-1260            Impact factor:   0.660


  5 in total

1.  Impact of 970 nm photobiomodulation therapy on wound healing in cellular models of hidradenitis suppurativa.

Authors:  Luisa Zupin; Giulia Ferri; Paola Maura Tricarico; Rossella Gratton; Cécile Nait-Meddour; Giulia Ottaviani; Sergio Crovella
Journal:  Lasers Med Sci       Date:  2020-07-09       Impact factor: 3.161

Review 2.  Medical Management of Hidradenitis Suppurativa with Non-Biologic Therapy: What's New?

Authors:  Soha Ghanian; Mika Yamanaka-Takaichi; Haley B Naik; Afsaneh Alavi
Journal:  Am J Clin Dermatol       Date:  2022-01-06       Impact factor: 6.233

3.  Dissecting Cellulitis of the Scalp: A Review and Case Studies of Surgical Reconstruction.

Authors:  Trajan A Cuellar; Daniel S Roh; Christian E Sampson
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-08-18

4.  Acellular dermal substitute use in the reconstruction of axillary hidradenitis suppurativa.

Authors:  A Dhannoon; C M Hurley; S Carr; A Hussey
Journal:  JPRAS Open       Date:  2021-12-08

Review 5.  Outcomes and Reliability of Perforator Flaps in the Reconstruction of Hidradenitis Suppurativa Defects: A Systemic Review and Meta-Analysis.

Authors:  Camille Vaillant; Yanis Berkane; Elise Lupon; Michael Atlan; Pascal Rousseau; Alexandre G Lellouch; Jérôme Duisit; Nicolas Bertheuil
Journal:  J Clin Med       Date:  2022-09-30       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.